- Commissioner Enhances FDA’s Commitment to Personalized Medicine
- Perfecting Policy on Stem Cells
- NIH and FDA Aim to Retool Regulatory Science
- DOE Leads Federal Funding for a Regional Innovation Cluster
- Certainty on the Science of Climate Change
- They’re Not Perfect Cells, But They’re Model Cells
- Genomic Medicine on the March
- President’s Budget Aims to Recharge Regional Innovation
- Event: The Science of Climate Change
- Progress in Bioethics
- The Top Science Progress Features of 2009
- Science Education Progress
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
Embryonic Stem Cells As Anti-cancer Labs
Amid the premature hype about induced pluripotent stem cells (hyped by everyone but the scientists who did the work themselves), the unique characteristics of embryonic stem cells as platforms for learning about human disease can too easily be lost. An important new study should help correct this oversight.
A distinguished team of Northwestern University researchers has found that a gene called Lefty that is only made in human embryonic stem cells (hESCs) suppresses the growth of melanoma and breast cancer cells. They also noted an increase in deaths of the killer cells. The hESC environment might make it possible to develop new cancer therapies.
Of course, the Bush administration and its allies prefer to wait out the clock in order to take the stem cell issue, which polls badly for them, off the table. Will the White House domestic policy council, which appears only to recognize science that vindicates their policy preferences, comment on the Northwestern teams’ result? We can live in hope.
Comments on this article


